Document is current
Any future updates will be listed below
-
Authors
Mitchell, Shannon Gwin http://orcid.org/0000-0002-2841-1085
Jester, Julia
Gryczynski, Jan
Whitter, Melanie
Fuller, Douglas
Halsted, Caroline
Schwartz, Robert P.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04188977 at ClinicalTrials.govDocuments that mention this clinical trial
Impact of COVID-19-related methadone regulatory flexibilities: views of state opioid treatment authorities and program staff
https://doi.org/10.1186/s13722-023-00417-7
-
Funding
Funding for this research was provided by:
National Institute on Drug Abuse (5U01DA046910)
- License Information
-
More Information
Article History
Received: 16 December 2022
Accepted: 9 October 2023
First Online: 17 October 2023
Declarations
:
: Human Subjects oversight was provided by the Western Institutional Review Board (WIRB).
: Not applicable.
: Unrelated to the present study, Dr. Mitchell is MPI on a NIDA study that was provided medication in-kind by Braeburn. Dr. Schwartz has provided consultation to Verily Life Sciences and Dr. Gryczynski reports part ownership of COG Analytics and a research grant from Indivior. Both have reported serving as PI on a NIDA grant that was provided medication in-kind by Indivior and Alkermes. All other authors report no additional conflicts of interest.
